Caliway Biopharmaceuticals developed CBL-514 to target abdominal fat cells, and researchers say it does more than shrink them. Details on how it works are at the link.
Recap by typeshit. Post by Facebook on Facebook.
A physio fielding years of peptide questions says strong studies are lacking, while noting that a lack of evidence doesn't prove they fail.
Up to half of participants in the two trials of the experimental drug ended up with only mild sleep apnea, per the post.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
The JAMA Network Open study scanned about 150,000 posts, and increased appetite was the top complaint. The authors say it can't prove the drug caused it.
She says the medications lower the odds of heart attack, stroke and cardiovascular death in patients with obesity, with or without diabetes.
Loading…